DeutschNewstral
Article
Seattle Times on 2024-02-06 15:08
Weight loss, diabetes drugs propel Eli Lilly to better-than-expected forecast for 2024
Related news
Diabetes, weight drugs earn Eli Lilly $4B in 2Qnwaonline.com- FEli Lilly & Co: Eli Lilly lifts outlook on bumper sales of diabetes and weight loss drugsft.com
- FEli Lilly lifts guidance on strong sales of diabetes and weight loss drugsft.com
Eli Lilly & Co: Eli Lilly to invest extra $5.3bn in manufacturing site for weight loss drugsFinancial Times- MEli Lilly weight reduction drug cuts threat of creating diabetes in trialmvtelegraph.com
- DAnalysts revamp Eli Lilly stock price target on weight-loss drugsdcourier.com
- WEli Lilly returns to RTP with $470M plant for diabetes drugswraltechwire.com
- MEli Lilly CEO on slicing tips, potential weight problems drug, Alzheimer’s trialmvtelegraph.com
Soaring sales of diabetes drug Mounjaro, widely used for weight loss, sends Eli Lilly to new heightstimesfreepress.com- LEndocrinology Drugs Market Size, Key Opportunities, Strategic Assessment, Strong Revenue | Oprating Vendors: AbbVie, Merck, AstraZeneca, Eli Lilly, Sanofi, Novo Nordisk…liverpoolstudentmedia.com
- FEli Lilly & Co: Eli Lilly launches cut-price version of blockbuster weight-loss drugft.com
- Eli Lilly & Co: Eli Lilly to seek obesity drug approval that could disrupt weight loss marketFinancial Times
- Eli Lilly & Co: Eli Lilly weight-loss drug found to address sleep apnoea in trialFinancial Times
Eli Lilly weight loss drug Zepbound approved by the FDANew York Post- MEli Lilly weight reduction drug tirzepatide knowledge launchedmvtelegraph.com
- DEli Lilly slumps after disappointing Zepbound weight-loss-drug trialdcourier.com
- Eli Lilly giving price info on advertised drugs via websiteSeattle Times
- FRoche and Eli Lilly drugs fail ‘inherited’ Alzheimer’s trialft.com